BRCA1 and ovarian cancer: To evaluate the antineoplastic activity of artesunate in ovarian cancer, we assessed the dose-dependent effect of artesunate on the viability of three epithelial ovarian cancer cell lines: Caov-3 (adenocarcinoma), UWB1.289 (high-grade serous carcinoma with a BRCA1 mutation), and OVCAR-3 (adenocarcinoma) using the CellTiter-Glo 2.0 assay.